NASDAQ:SNDX

Syndax Pharmaceuticals Stock Insider Trading

etoro logo Buy SNDX
*Your capital is at risk
$18.34
-0.0500 (-0.272%)
At Close: Jun 03, 2026

Syndax Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -11.26. In total, the insiders bought 4.28M and sold 545.78K SNDX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-11.26
Buy 4.28M shares
Sell 545.78K shares
73% Buy Activity
Weak Negative Correlation
Buy Signal Low Confidence
Feb 04, 2026

Analysis Breakdown:

  • Weakened by a contradictory negative Insider Power Score.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 01, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 6 847
Value: $130.0K
Jun 01, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 177
Value: $22.4K
Feb 09, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 3 410
Value: $71.7K
Feb 09, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 17 159
Value: $360.8K
Feb 06, 2026
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 7 412
Value: $152.8K
Feb 06, 2026
Sell
Common Stock
S-Sale
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 2 082
Value: $42.9K
Feb 04, 2026
Buy
Common Stock
A-Award
Legault Pierre
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Common Stock
A-Award
Rizo Aleksandra
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Common Stock
A-Award
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 36 000
Value: $735.5K
Feb 04, 2026
Buy
Common Stock
A-Award
Huber Martin H. Jr.
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Stock Options (Right to buy)
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 118 000
Value: $2.41M
Feb 04, 2026
Buy
Common Stock
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 73 000
Value: $1.49M
Feb 04, 2026
Buy
Stock Options (Right to buy)
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 440 000
Value: $8.99M
Feb 04, 2026
Buy
Common Stock
A-Award
Metzger Michael A
Chief Executive Officer
CEO / President 144 600
Value: $2.95M
Feb 04, 2026
Buy
Common Stock
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 30 750
Value: $628.2K
Feb 04, 2026
Buy
Common Stock
A-Award
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 21 500
Value: $439.2K
Feb 04, 2026
Buy
Common Stock
A-Award
Jarrett Jennifer
Director
Director 24 000
Value: $490.3K
Feb 04, 2026
Buy
Stock Options (Right to buy)
A-Award
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 144 700
Value: $2.96M
Feb 04, 2026
Buy
Common Stock
A-Award
Botwood Nicholas A.j.
Head Of R&d, Cmo
Officer 24 000
Value: $490.3K
Feb 04, 2026
Buy
Common Stock
A-Award
Podlesak Dennis
Director
Director 48 000
Value: $980.6K
Feb 04, 2026
Buy
Common Stock
A-Award
Katkin Keith
Director
Director 24 000
Value: $490.3K
Jan 30, 2026
Buy
Common Stock
J-Other
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 219
Value: $10.3K
Dec 01, 2025
Sell
Common Stock
G-Gift
Goldan Keith A.
Chief Financial Officer
C-Suite Officer 1 224
Value: $0
Sep 08, 2025
Buy
Common Stock
M-Exempt
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $1.71M
Sep 08, 2025
Sell
Common Stock
S-Sale
Metzger Michael A
Chief Executive Officer
CEO / President 157 307
Value: $2.58M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT SYNDAX PHARMACEUTICALS INC
Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that b...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE